Image source: Roche.
A bunch of new, expensive, and incrementally better multiple sclerosis therapies approved over the past decade sent global spending on such drugs skyrocketing to nearly $20 billion last year.
Those of you that understand this awful disease will be glad to learn Roche (NASDAQOTH: RHHBY) has a drug on deck that could send all those rookies back to the minor leagues.